Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2007 1
2008 1
2010 1
2011 5
2012 1
2013 5
2014 6
2015 10
2016 9
2017 11
2018 9
2019 12
2020 11
2021 11
2022 14
2023 11
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

115 results

Results by year

Filters applied: . Clear all
Page 1
CSNK1A1/CK1alpha suppresses autoimmunity by restraining the CGAS-STING1 signaling.
Pan M, Hu T, Lyu J, Yin Y, Sun J, Wang Q, Xu L, Hu H, Wang C. Pan M, et al. Autophagy. 2024 Feb;20(2):311-328. doi: 10.1080/15548627.2023.2256135. Epub 2024 Jan 25. Autophagy. 2024. PMID: 37723657
Consistently, SSTC3, a selective CSNK1A1 agonist, significantly attenuated the response of the CGAS-STING1 signaling by promoting STING1 autophagic degradation. ...Taken together, our study reveals a novel regulatory role of CSNK1A1 in the autophagic degradation of …
Consistently, SSTC3, a selective CSNK1A1 agonist, significantly attenuated the response of the CGAS-STING1 signaling by promoting STI …
Csnk1a1 inhibition modulates the inflammatory secretome and enhances response to radiotherapy in glioma.
Liu G, Li H, Zhang W, Yu J, Zhang X, Wu R, Niu M, Liu X, Yu R. Liu G, et al. J Cell Mol Med. 2021 Aug;25(15):7395-7406. doi: 10.1111/jcmm.16767. Epub 2021 Jul 3. J Cell Mol Med. 2021. PMID: 34216174 Free PMC article.
In this study, we evaluated the anti-tumour effect of Csnk1a1 suppression in GBM cells in vitro and in vivo. We found that down-regulation of Csnk1a1 or inhibition by D4476, a Csnk1a1 inhibitor, reduced GBM cell proliferation efficiently in both Tp53 wild-typ …
In this study, we evaluated the anti-tumour effect of Csnk1a1 suppression in GBM cells in vitro and in vivo. We found that down-regul …
Knockdown of Csnk1a1 results in preimplantation developmental arrest in mice.
Ma Z, Zheng H, Li X, Yu B, Peng H. Ma Z, et al. Theriogenology. 2023 Mar 1;198:30-35. doi: 10.1016/j.theriogenology.2022.12.018. Epub 2022 Dec 15. Theriogenology. 2023. PMID: 36542875
This study was established to analyze the expression and localization of CSNK1A1 and its function in early embryonic development in mice. Csnk1a1 mRNA and protein are expressed in multiple mouse tissues including the ovary. ...CSNK1A1 protein was also mainly …
This study was established to analyze the expression and localization of CSNK1A1 and its function in early embryonic development in m …
Upregulation of CSNK1A1 induced by ITGB5 confers to hepatocellular carcinoma resistance to sorafenib in vivo by disrupting the EPS15/EGFR complex.
Gu L, Jin X, Liang H, Yang C, Zhang Y. Gu L, et al. Pharmacol Res. 2023 Jun;192:106789. doi: 10.1016/j.phrs.2023.106789. Epub 2023 May 4. Pharmacol Res. 2023. PMID: 37149115 Free article.
Mechanistically, unbiased mass spectrometry analysis using ITGB5 antibodies revealed that ITGB5 interacts with EPS15 to prevent the degradation of EGFR in HCC cells, which activates AKT-mTOR signaling and the MAPK pathway to reduce the sensitivity of HCC cells to sorafenib. In ad …
Mechanistically, unbiased mass spectrometry analysis using ITGB5 antibodies revealed that ITGB5 interacts with EPS15 to prevent the degradat …
Genetic abnormalities and pathophysiology of MDS.
Hosono N. Hosono N. Int J Clin Oncol. 2019 Aug;24(8):885-892. doi: 10.1007/s10147-019-01462-6. Epub 2019 May 15. Int J Clin Oncol. 2019. PMID: 31093808 Review.
Newer genomic technologies, such as single-nucleotide polymorphism array and next-generation sequencing, revealed the heterozygous deletions resulting in haploinsufficient gene expression (e.g., CSNK1A1, DDX41 on chromosome 5, CUX1, LUC7L2, EZH2 on chromosome 7) involved i …
Newer genomic technologies, such as single-nucleotide polymorphism array and next-generation sequencing, revealed the heterozygous deletions …
Csnk1a1 inhibition has p53-dependent therapeutic efficacy in acute myeloid leukemia.
Järås M, Miller PG, Chu LP, Puram RV, Fink EC, Schneider RK, Al-Shahrour F, Peña P, Breyfogle LJ, Hartwell KA, McConkey ME, Cowley GS, Root DE, Kharas MG, Mullally A, Ebert BL. Järås M, et al. J Exp Med. 2014 Apr 7;211(4):605-12. doi: 10.1084/jem.20131033. Epub 2014 Mar 10. J Exp Med. 2014. PMID: 24616378 Free PMC article.
Normal hematopoietic stem and progenitor cells (HSPCs) were relatively less affected by shRNA-mediated knockdown of Csnk1a1. To identify downstream mediators of Csnk1a1 critical for leukemia cells, we performed an in vivo pooled shRNA screen and gene expression prof …
Normal hematopoietic stem and progenitor cells (HSPCs) were relatively less affected by shRNA-mediated knockdown of Csnk1a1. To ident …
CSNK1A1, KDM2A, and LTB4R2 Are New Druggable Vulnerabilities in Lung Cancer.
Sauta E, Reggiani F, Torricelli F, Zanetti E, Tagliavini E, Santandrea G, Gobbi G, Strocchi S, Paci M, Damia G, Bellazzi R, Ambrosetti D, Ciarrocchi A, Sancisi V. Sauta E, et al. Cancers (Basel). 2021 Jul 12;13(14):3477. doi: 10.3390/cancers13143477. Cancers (Basel). 2021. PMID: 34298691 Free PMC article.
Next, to identify relevant therapeutic targets, we integrated dependency data with pharmacological data and TCGA gene expression information. Through this analysis, we identified CSNK1A1, KDM2A, and LTB4R2 as relevant druggable essentiality genes in lung cancer. ...
Next, to identify relevant therapeutic targets, we integrated dependency data with pharmacological data and TCGA gene expression information …
Targeting Csnk1a1 in leukemia.
Stegmaier K. Stegmaier K. J Exp Med. 2014 Apr 7;211(4):594. doi: 10.1084/jem.2114insight1. J Exp Med. 2014. PMID: 24711612 Free PMC article. No abstract available.
Collaborative effect of Csnk1a1 haploinsufficiency and mutant p53 in Myc induction can promote leukemic transformation.
Fuchs SNR, Stalmann USA, Snoeren IAM, Bindels E, Schmitz S, Banjanin B, Hoogenboezem RM, van Herk S, Saad M, Walter W, Haferlach T, Seillier L, Saez-Rodriguez J, Dugourd AJF, Lehmann KV, Ben-Neriah Y, Gleitz HFE, Schneider RK. Fuchs SNR, et al. Blood Adv. 2024 Feb 13;8(3):766-779. doi: 10.1182/bloodadvances.2022008926. Blood Adv. 2024. PMID: 38147624 Free PMC article.
Additionally, Trp53 was disrupted as the most frequently comutated gene in del(5q) MDS using CRISPR/Cas9 editing in hematopoietic progenitors of wild-type (WT), Csnk1a1-/+, Egr1-/+, Csnk1a1/Egr1-/+ mice. A transplantable acute leukemia only developed in the Csnk1 …
Additionally, Trp53 was disrupted as the most frequently comutated gene in del(5q) MDS using CRISPR/Cas9 editing in hematopoietic progenitor …
Rps14, Csnk1a1 and miRNA145/miRNA146a deficiency cooperate in the clinical phenotype and activation of the innate immune system in the 5q- syndrome.
Ribezzo F, Snoeren IAM, Ziegler S, Stoelben J, Olofsen PA, Henic A, Ferreira MV, Chen S, Stalmann USA, Buesche G, Hoogenboezem RM, Kramann R, Platzbecker U, Raaijmakers MHGP, Ebert BL, Schneider RK. Ribezzo F, et al. Leukemia. 2019 Jul;33(7):1759-1772. doi: 10.1038/s41375-018-0350-3. Epub 2019 Jan 16. Leukemia. 2019. PMID: 30651631
RPS14, CSNK1A1, and miR-145 are universally co-deleted in the 5q- syndrome, but mouse models of each gene deficiency recapitulate only a subset of the composite clinical features. We analyzed the combinatorial effect of haploinsufficiency for Rps14, Csnk1a1, and miR …
RPS14, CSNK1A1, and miR-145 are universally co-deleted in the 5q- syndrome, but mouse models of each gene deficiency recapitulate onl …
115 results